TREBL-1 (NHL31)

An Open label, Multicentre, Phase I study of Ibrutinib, Rituximab, Valaciclovir and 3rd Party EBV specific T cells in Patients with immunosuppression related EBV-positive Brain and/or Systemic B cell lymphomas, that are relapsed/refractory or unsuitable for standard first-line treatments.
Menu